ACC House Call: Current SGLT-2 Inhibitor Standing


A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.

The SGLT-2 inhibitor drug class has progressed quickly in clinical cardiometabolic assessment and real-life use—from the management and reduction of type 2 diabetes (T2D) glucose levels, to the prevention of chronic kidney disease risk, and now to benefit for certain patients’ heart failure risks.

What will dictate their marketed labels and overall use among patients is the continuation of research beyond the current coronavirus (COVID-19) pandemic—and the dissemination of such research at future major meetings.

In a special edition House Call video interview with HCPLive®, Muthiah Vaduganathan, MD, MPH, a cardiologist at the Center for Advanced Heart Disease at Brigham and Women's Hospital, detailed what new trends and findings would have highlighted SGLT2 discussion at the American College of Cardiology (ACC) 2020 Scientific Sessions prior to its cancellation.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
A panel of 5 cardiovascular experts
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
© 2024 MJH Life Sciences

All rights reserved.